SCHEMBL1198261

SCHEMBL1198261

CCc1sc(-c2cccc(C(F)(F)F)c2)nc1CO

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
MAPT P10636 1/20 0.54
ALDH1A1 P00352 3/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
DCK P27707 1/20 0.45
PPARG P37231 2/20 0.44
PPARA Q07869 2/20 0.44
PPARD Q03181 1/20 0.44
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
ALPL P05186 1/20 0.40
ALPI P09923 1/20 0.40
MCL1 Q07820 1/20 0.40
RORB Q92753 1/20 0.40
F2RL3 Q96RI0 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16399145 0.90 MEN1 (0.52) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL1198661 0.88 MEN1 (0.49) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL1199289 0.84 ALDH1A1 (0.56) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL13650688 0.83 ALDH1A1 (0.51) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL1198943 0.82 ALDH1A1 (0.63) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL1198088 0.82 ALDH1A1 (0.50) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL12875849 0.81 DCK (0.46) MEN1KMT2AMAPTALDH1A1DCK
SCHEMBL1199076 0.80 ALDH1A1 (0.61) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL16399681 0.80 L3MBTL1 (0.68) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL16399207 0.79 MEN1 (0.48) MEN1KMT2AMAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A MEN1 2661/4885KMT2A 3197/4885MAPT 4667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.